NasdaqOn RegSHO · 5 days in a row
$4.00▼ 0.50%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $8.0MShares out 2.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
36- 5d agoPre-market26.10.20 19:358-KKey event#●●●#●●●
Quoin Pharmaceuticals Ltd.Bullish
Quoin Pharmaceuticals announced the publication of a peer-reviewed manuscript in 'Dermatology and Therapy' detailing a pediatric compassionate-use case for its Netherton Syndrome treatment, QRX003. The patient achieved clear skin and complete itch relief over 21 months of treatment, while the company expects to complete recruitment for its ongoing Phase 2/3 study by the end of 2026 and report topline data in Q2 2027.…more
$4.00-0.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14Pre-market26.10.14 19:358-KKey event
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals announced that its lead product candidate, QRX003, has been granted Orphan Drug Designation by the European Medicines Agency (EMA) for the treatment of Peeling Skin Syndrome. This designation provides the company with benefits including scientific advice, fee reductions, and 10 years of market exclusivity in Europe upon marketing authorization. The company remains on track to initiate its first formal clinical trial for this indication before the end of the year.…more
$4.00-0.50%vs prev closeView filingShare - 10.7After-hours26.10.08 06:13SCHEDULE 13G/AOwnership
Quoin Pharmaceuticals Ltd.
This is a SCHEDULE 13G/A filing by Ikarian Capital, LLC regarding its beneficial ownership in Quoin Pharmaceuticals Ltd. The reporting entity has submitted an update to the SEC concerning its existing equity position.…more
$4.00-0.50%vs prev closeView filingShare
35 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 5d agoPre-market26.10.20 19:30#●●●#●●●
Quoin Pharmaceuticals Publishes Peer-Reviewed Case Report on QRX003 for Netherton Syndrome…more
Quoin Pharmaceuticals announced the publication of a peer-reviewed case report demonstrating the efficacy of QRX003 in treating Netherton Syndrome. The company expects to report topline data from its ongoing Phase 2/3 study in the second quarter of 2027.…more
$4.00-0.50%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.14Pre-market26.10.14 19:31
●●●●●●●● ●●●●● ●●●●●●
Quoin Pharmaceuticals' lead candidate QRX003 has been granted Orphan Drug Designation by the EMA for treating Peeling Skin Syndrome. This milestone provides the company with 10 years of market exclusivity in Europe and various regulatory incentives.…more
$4.00-0.50%vs prev closeShareBenzinga - 10.6Pre-market26.10.06 19:30
●●●●●●●● ●●●●● ●●●●●●
Quoin Pharmaceuticals announced that a peer-reviewed paper on its investigational Netherton Syndrome treatment, QRX003, has been accepted for publication. While the company reports positive clinical progress, the drug remains in late-stage clinical trials pending final regulatory approval.…more
$4.00-0.50%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report